Trials on Impella in high-risk PCI, percutaneous left atrial appendage closure, CTO-PCI, and spironolactone in HFpEF are Mandrola’s most anticipated at the upcoming 2026 ACC meeting in New Orleans. theheart.org on Medscape

Read the full article on medscape.com